DEVELOPMENT PIPELINE
Stage | Product | Partner |
![]() |
ARX788 αHER2 ADC – HER2+Breast Cancer(1) | ![]() |
![]() |
ARX517 PSMA ADC - Oncology(2) | ![]() |
![]() |
CD70 ADC - Oncology(3) | ![]() |
![]() |
Bi-specific Anti-CD3 X Folate | ![]() |
![]() |
ARX618 PEG-FGF21 – NASH | ![]() |
![]() |
ARX720 Relaxin – Heart Failure | ![]() |
![]() |
Imrestor - Mastitis in Cattle(7) | ![]() |
![]() |
ADCs – Oncology | ![]() |
![]() |
Multi-Specific ADCs(9) | ![]() |
(1) Ambrx owns the worldwide rights to ARX788, with the exception of the People's Republic Of China, for which the rights to ARX788 have been licensed to Zhejiang Medicine Co., Ltd. (2) Potential indications include prostate cancer and glioblastoma multiforme. (3) Potential indications include renal cell carcinoma and nasopharyngeal carcinoma. (8) Potential indications include oncology and autoimune/inflamatory diseases. |
Key | Description |
![]() |
Marketed |
![]() |
Phase 2 |
![]() |
Phase 1 |
![]() |
Preclinical |
![]() |
Discovery |